Objective
Market
Strategy
Company's
Future
Senior
Management
Scientific
Advisory Board
People
at Work
|
CIMM
was set up to engage in research and development of viral therapies.
CIMM has isolated
a self-replicating hepatitis-C virus, believed to be the only such virus
in the world. This virus has the potential of opening up whole new avenues
in HCV research and therapies. Among other benefits, because CIMM’s HCV
isolate replicates in vitro, proposed therapies can be tested quickly without
expensive and time-consuming animal (simian) tests.
Utilizing it’s
own HCV isolate, CIMM has developed a drug, XHA, which has shown promise
in treating HCV infection. Preliminary toxicity testing on XHA is also
very promising.
CIMM
has also developed a drug, XFA, which has shown promise in treating feline
leukemia. This itself is a very valuable market and can be entered without
the expensive and time-consuming process required for human drug testing
and approval.
CIMM
has made substantial progress on a Kupffer cell therapy (replacement of
selected liver cellsr liver patients awaiting transplants) which could
be of great benefit in prolonging survival until a transplant is available. |
